KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Gains from Sales and Divestitures (2022)

AbCellera Biologics (ABCL) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $239751.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Gains from Sales and Divestitures changed N/A year-over-year to $239751.0, compared with a TTM value of $239751.0 through Dec 2022, changed N/A, and an annual FY2022 reading of $239751.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $239751.0 for Q4 2022 at AbCellera Biologics, up from $187501.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $239751.0 in Q4 2022 and bottomed at $43387.0 in Q1 2022.